Interpace Biosciences, a molecular diagnostics company specializing in tests for thyroid cancer, has withdrawn its plans for an initial public offering on the Nasdaq. The Parsippany, New Jersey-based company had most recently filed in October 2026 to raise approximately $20 million through the sale of 3.1 million shares at a proposed price range of $6 to $7 per share.
The withdrawal marks a change in the company’s planned public-market strategy after its initial filing in September 2026.
Proposed IPO Structure
Interpace Biosciences had planned to raise $20 million by offering approximately 3.1 million shares to investors. The proposed pricing range was set at $6 to $7 per share.
The company intended to list on the Nasdaq under the ticker symbol IDXG. Lake Street Capital Markets and Laidlaw & Company (UK) were scheduled to serve as joint bookrunners for the transaction.
However, the company withdrew the proposed offering on Wednesday. The available announcement did not disclose the reason for the withdrawal or indicate whether Interpace intends to pursue another public offering.
Company Background and Diagnostic Focus
Founded in 1986 and headquartered in Parsippany, New Jersey, Interpace Biosciences provides molecular diagnostic testing services focused on thyroid cancer.
Its diagnostic business operates within the healthcare and biotechnology sectors, serving a specialized area of cancer testing. The supplied announcement does not provide additional details about individual diagnostic products, financial performance, revenue, or clinical development activities.
Closing Insights
Interpace Biosciences’ withdrawal removes its proposed $20 million Nasdaq offering from the near-term IPO pipeline. The company had planned to use the public-market transaction to raise capital through a share offering, but its decision leaves the timing of any future listing uncertain.
Investors will be watching for further disclosures regarding the company’s financing strategy and whether it intends to revisit the public markets. For now, no revised IPO timetable or explanation for the withdrawal has been provided.